Moreover, three HER2 inhibitors (lapatinib, neratinib, and tucatinib) were approved as third-line regimens for the treatment of HER2-positive breast cancer in combination with trastuzumab and/or capecitabine [215] (Fig. 3j). The gene discussed is ERBB2; the disease is breast carcinoma.